

2010

ORIGINAL INNOVATION

Dr. Bredesen conceives first Alzheimer's Precision Medicine Approach

2012

PATIENT ZERO

First patient (Judy Benjamin) treated with ReCODE precursor

2013

BREAKTHROUGH STUDY

Landmark Paper: *Neuroprotective Sirtuin Ratio Reversed by ApoE4*

2014

LANDMARK PUBLICATION

First publication documenting reversal of cognitive decline in Alzheimer's. (Patients treated with ReCODE precursor.)

2016

APOE4 LANDMARK

Study showing ApoE4 is a transcription factor that binds DNA with high affinity, putting ApoE4 carriers at increased risk for Alzheimer's disease

2017

THE SCIENCE, INCORPORATED

Apollo Health founded to scale and commercialize the ReCODE protocol

2018

ReCODE 1.0 LAUNCH

Preliminary Productization and Commercialization



2020

ReCODE 2.0 & PreCODE LAUNCH

Product Line Upgrade and Expansion

PRACTITIONER RECRUITMENT & EDUCATION

ReCODE 2.0 Training Program Launch



2021

LANDMARK STUDY #1

First study scaling ReCODE for clinical practice.



2022

FIRST CLINICAL TRIAL

ReCODE, A Precision Medicine Approach to Alzheimer's Disease

2023

INDEPENDENT CONFIRMATION

Validation of ReCODE's efficacy in reversing cognitive decline

2024

SUSTAINED COGNITIVE IMPROVEMENT

Publication documenting sustained improvement for over a decade

1000TH PRACTITIONER CERTIFIED

ReCODE Training Program continues rapid growth

The New York Times BEST SELLER

"End of Alzheimer's" sells millionth copy



2025

LONG-TERM EFFICACY ACHIEVEMENT

Patient Zero Judy Benjamin completes 2,800-mile walk across America

LANDMARK STUDY #2

First study establishing ReCODE's effectiveness for reducing depression

SECOND CLINICAL TRIAL

Randomized Controlled Trial completed, preprint



2026

EFFICACY CLINICALLY PROVEN

Randomized Controlled Trial peer-reviewed publication (~September, 2026)